Companies Dominating the Aplastic Anemia Treatment Landscape
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eisai Co., Ltd.
- Allergan, Inc.
- TauRx Therapeutics Ltd.
- AbbVie Inc.
- Novartis AG
- Siemens Healthcare GmbH
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- Bayers AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of surface mount reed relays is evaluated at USD 7.36 billion.
The aplastic anemia treatment market size was valued at USD 7.07 billion in 2024 and is expected to reach USD 13.67 billion by 2037, expanding at around 5.2% CAGR during the forecast period i.e., between 2025-2037. The increasing number of people being diagnosed with aplastic anemia, improved access to healthcare, and availability of new and improved treatment options will boost the market growth.
North America industry is anticipated to hold largest revenue share of NA% by 2037, due to availability of advanced treatment options for aplastic anemia, such as bone marrow transplantation, immunosuppressive therapy, and blood transfusions.
The major players in the market are F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Allergan, Inc., TauRx Therapeutics Ltd., AbbVie Inc., Novartis AG, Siemens Healthcare GmbH, Pfizer, Inc., Bristol-Myers Squibb Company, Bayers AG
